Leerink Partnrs Issues Negative Outlook for Danaher Earnings

Danaher Co. (NYSE:DHR) – Stock analysts at Leerink Partnrs lowered their Q1 2025 earnings estimates for shares of Danaher in a report issued on Wednesday, January 29th. Leerink Partnrs analyst P. Souda now anticipates that the conglomerate will post earnings per share of $1.63 for the quarter, down from their prior forecast of $2.02. The consensus estimate for Danaher’s current full-year earnings is $7.77 per share. Leerink Partnrs also issued estimates for Danaher’s Q4 2025 earnings at $2.43 EPS, FY2025 earnings at $7.65 EPS, Q1 2026 earnings at $1.93 EPS, Q2 2026 earnings at $1.96 EPS, Q3 2026 earnings at $2.05 EPS, Q4 2026 earnings at $2.66 EPS and FY2026 earnings at $8.60 EPS.

DHR has been the subject of a number of other reports. UBS Group reduced their target price on shares of Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research note on Wednesday, October 23rd. Jefferies Financial Group lowered their price target on Danaher from $285.00 to $260.00 and set a “buy” rating on the stock in a research report on Wednesday, January 29th. Wolfe Research upgraded shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 target price for the company in a research note on Thursday, October 31st. Scotiabank initiated coverage on Danaher in a report on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 price objective on the stock. Finally, Stephens reaffirmed an “overweight” rating and set a $315.00 target price on shares of Danaher in a report on Wednesday, October 23rd. Seven research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $278.00.

Danaher Price Performance

Shares of DHR stock opened at $214.09 on Monday. Danaher has a 52-week low of $214.03 and a 52-week high of $281.70. The firm’s 50 day moving average price is $235.40 and its two-hundred day moving average price is $253.09. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40. The stock has a market cap of $154.64 billion, a PE ratio of 40.55, a PEG ratio of 2.80 and a beta of 0.83.

Danaher (NYSE:DHR) last announced its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same period in the prior year, the firm earned $2.09 earnings per share.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Friday, December 27th were given a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.50%. The ex-dividend date of this dividend was Friday, December 27th. Danaher’s dividend payout ratio is presently 20.45%.

Insider Buying and Selling

In related news, SVP Brian W. Ellis sold 5,700 shares of the company’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the completion of the sale, the senior vice president now owns 20,230 shares in the company, valued at approximately $4,534,149.90. This represents a 21.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Wedge Capital Management L L P NC increased its position in Danaher by 3.2% during the 3rd quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock valued at $342,000 after purchasing an additional 38 shares during the period. Meridian Financial Partners LLC raised its stake in Danaher by 4.4% in the third quarter. Meridian Financial Partners LLC now owns 957 shares of the conglomerate’s stock worth $266,000 after buying an additional 40 shares in the last quarter. Kovack Advisors Inc. lifted its holdings in Danaher by 3.4% during the third quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate’s stock worth $346,000 after buying an additional 41 shares during the period. Well Done LLC boosted its holdings in shares of Danaher by 1.2% in the 3rd quarter. Well Done LLC now owns 3,551 shares of the conglomerate’s stock valued at $987,000 after buying an additional 42 shares in the last quarter. Finally, Waypoint Capital Advisors LLC grew its stake in Danaher by 0.9% during the 3rd quarter. Waypoint Capital Advisors LLC now owns 4,520 shares of the conglomerate’s stock worth $1,257,000 after buying an additional 42 shares during the last quarter. Institutional investors own 79.05% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.